Skip to main content

Advertisement

SpringerLink
Log in

Role of topical interferon alpha-2b in ‘mitomycin-C-resistant’ ocular surface squamous neoplasia: our preliminary findings

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report the clinical presentation of mitomycin-C (MMC)-resistant ocular surface squamous neoplasia (OSSN) and its treatment outcome with topical interferon alpha-2b (IFNα-2b).

Methods

A prospective, non-randomised, pilot study enrolling clinically diagnosed OSSN patients. The inclusion criterion was resistance of OSSN to standard topical MMC (0.02%) chemotherapy. The resistance was defined as ‘no clinical response’ in the terms of reduction in tumour size, extension and vascularity after minimum 6 weeks ‘on-cycles’ of MMC. Any previous surgical intervention or recurrent OSSN lesions were excluded. Topical MMC was stopped in all, and topical IFNα-2b (1million IU/ml) eyedrops were prescribed to each patient. At first presentation, the clinical features and side-effect profile of MMC was noted and therapeutic effect of IFNα-2b was clinically monitored at each follow-up. Topical immunotherapy was continued for 24 weeks and a minimum follow-up of 12 weeks was observed after stopping IFNα-2b.

Results

Six patients with a mean age of 62 years met the inclusion criteria. At presentation, all had unilateral, circumscribed, sessile and unifocal lesions with mean dimensions of 7.67 × 5.17 mm. Four patients had temporal lesions while surface keratin, pigmentation and corneal involvement were noted in three lesions, separately. All lesions had dilated and tortuous feeder vessels. All six tumours resolved completely over a mean tumour resolution time of 16 weeks while the total duration of IFNα-2b treatment was 24 weeks. After stopping immunotherapy, a mean of 14.5 weeks follow-up was observed. None showed any recurrence. The approximate cost of total therapy session was 8400 Indian rupees.

Conclusion

The OSSN lesions showing ‘less or no response’ to topical MMC may be shifted to topical recombinant IFNα-2b before proceeding for a surgical excision.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nanji AA, Moon CS, Galor A, Sein J, Oellers P, Karp CL (2014) Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. Ophthalmology 121:994–1000

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sturges A, Butt AL, Lai JE, Chodosh J (2008) Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. Ophthalmology 115:1297–1302

    Article  PubMed  Google Scholar 

  3. Poothullil AM, Colby KA (2006) Topical medical therapies for ocular surface tumors. Semin Ophthalmol 21:161–169

    Article  PubMed  Google Scholar 

  4. Wilson MW, Hungerford JL, George SM, Madreperla SA (1997) Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol 124:303–311

    Article  CAS  PubMed  Google Scholar 

  5. Yeatts RP, Ford JG, Stanton CA, Reed JW (1995) Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Ophthalmology 102:1338–1344

    Article  CAS  PubMed  Google Scholar 

  6. Shah SU, Kaliki S, Kim HJ, Lally SE, Shields JA, Shields CL (2012) Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification. Arch Ophthalmol 130:159–164

    Article  CAS  PubMed  Google Scholar 

  7. Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14:35–48

    Article  PubMed  Google Scholar 

  8. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6:1769–1792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041–1048

    Article  CAS  PubMed  Google Scholar 

  10. Ashkenazy N, Karp CL, Wang G, Acosta CM, Galor A (2017) Immunosuppression as a possible risk factor for interferon nonresponse in ocular surface squamous neoplasia. Cornea 36:506–510

    Article  PubMed  PubMed Central  Google Scholar 

  11. Tabin G, Levin S, Snibson G, Loughnan M, Taylor H (1997) Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology 104:485–492

    Article  CAS  PubMed  Google Scholar 

  12. Stone DU, Butt AL, Chodosh J (2005) Ocular surface squamous neoplasia: a standard of care survey. Cornea 24:297–300

    Article  PubMed  Google Scholar 

  13. Shields CL, Kaliki S, Kim HJ, Al-Dahmash S, Shah SU, Lally SE, Shields JA (2013) Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification. Cornea 32:248–256

    Article  PubMed  Google Scholar 

  14. Shields CL, Demirci H, Karatza E, Shields JA (2004) Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors. Ophthalmology 111:1747–1754

    Article  PubMed  Google Scholar 

  15. Kao AA, Galor A, Karp CL, Abdelaziz A, Feuer WJ, Dubovy SR (2012) Clinicopathologic correlation of ocular surface squamous neoplasms at Bascom Palmer Eye Institute: 2001–2010. Ophthalmology 119:1773–1776

    Article  PubMed  Google Scholar 

  16. Kieval JZ, Karp CL, AbouShousha M, Galor A, Hoffman RA, Dubovy SR, Wang J (2012) Ultra-high resolution optical coherence tomography for differentiation of ocular surface squamous neoplasia and pterygia. Ophthalmology 119:481–486

    Article  PubMed  Google Scholar 

  17. Xu Y, Zhou Z, Xu Y, Wang M, Liu F, Qu H, Hong J (2012) The clinical value of in vivo confocal microscopy for diagnosis of ocular surface squamous neoplasia. Eye 26:781–787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Maskin SL (1994) Regression of limbal epithelial dysplasia with topical interferon (letter). Arch Ophthalmol 112:1145–1146

    Article  CAS  PubMed  Google Scholar 

  19. Boehm MD, Huang AJ (2004) Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology 111:1755–1761

    Article  PubMed  Google Scholar 

  20. Singh M, Gautam N, Gupta A, Kaur M (2016) Interferon alfa-2b in the management of recurrent conjunctival papillomatosis. Indian J Ophthalmol 64:778–780

    Article  PubMed  PubMed Central  Google Scholar 

  21. Peksayar G, Altan-Yaycioglu R, Onal S (2003) Excision and cryosurgery in the treatment of conjunctival malignant epithelial tumours. Eye (Lond) 17:228–232

    Article  CAS  Google Scholar 

  22. Siganos CS, Kozobolis VP, Christodoulakis EV (2002) The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea 21:12–16

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India

    Manpreet Singh, Natasha Gautam & Manpreet Kaur

Authors
  1. Manpreet Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natasha Gautam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manpreet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manpreet Singh.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The written informed consent was obtained from all the participants before starting topical interferon therapy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, M., Gautam, N. & Kaur, M. Role of topical interferon alpha-2b in ‘mitomycin-C-resistant’ ocular surface squamous neoplasia: our preliminary findings. Int Ophthalmol 39, 295–301 (2019). https://doi.org/10.1007/s10792-017-0811-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-017-0811-0

Keywords

Search

Navigation